Iqvia reported third-quarter revenue of $4.4 billion, up nearly 8% year over year, and adjusted diluted earnings per share of $3.34, up 11%. Management raised its 2026 outlook, including a 29-basis-point increase to the midpoint of its previous revenue guidance.
Iqvia's leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.
The company's next-generation solutions could lose traction among clients or fail to gain traction with regulatory bodies.
|
Metric
|
IQV
|
ICLR
|
FTRE
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.04 | 28.64 | 159.26 |
Price/Book Value | 6.62 | 1.73 | 3.86 |
Price/Sales | 2.61 | 1.97 | 0.75 |
Price/Cash Flow | 16.85 | 17.61 | 35.62 |
|
Metric
|
IQV
|
ICLR
|
FTRE
|
|---|---|---|---|
Quick Ratio | 0.74 | 1.27 | 0.88 |
Current Ratio | 0.83 | 1.32 | 0.97 |
Interest Coverage | 2.93 | 3.49 | 0.36 |
|
Metric
|
IQV
|
ICLR
|
FTRE
|
|---|---|---|---|
Return on Assets (Normalized) | 7.28% | 3.47% | −0.67% |
Return on Equity (Normalized) | 34.12% | 6.12% | −3.36% |
Return on Invested Capital (Normalized) | 12.43% | 5.69% | 2.54% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|tGz?L@m | LOCK|QgF | $258B | |||
| Danaher Corp
DHR
| LOCK|<qK&mv? | LOCK|z<< | $163B | |||
| Agilent Technologies Inc
A
| LOCK|Rp&h>#H | LOCK|Nlr | $49B | |||
| Waters Corp
WAT
| LOCK|c%wmr$ | LOCK|!d$ | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|$NtBnW!% | LOCK|!! | $43B | |||
| Illumina Inc
ILMN
| LOCK|!@<<@&$ | LOCK|%S&@N | $36B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|%><@?&? | LOCK|!l#V | $34B | |||
| Labcorp Holdings Inc
LH
| LOCK|l<pQ@?Y | LOCK|!!HD | $29B | |||
| Quest Diagnostics Inc
DGX
| LOCK|@>tB&R | LOCK|YM>M | $28B |
United States